Clinical characteristics and systemic therapies administered to first-time patients at a tertiary psoriasis outpatient clinic

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The aim of this study was to describe the clinical characteristics and the systemic therapies given to a cohort of patients attending for the first time our tertiary psoriasis outpatient clinic. METHODS: Data were extracted from an electronic database where the patients, mostly eligible for systemic therapies, are consecutively recorded. Based on skin disease severity the subjects were classified into three groups: group 1, mild psoriasis (MP; Psoriasis Area Severity Index [PASI]≤5); group 2, mild-to-moderate psoriasis (MMP; 5<PASI<10); group 3, moderate-to-severe psoriasis (MSP; PASI>10). RESULTS: Of the 289 patients studied, 88 (30.4%) presented with MP, 91 (31.5%) with MMP, and 110 (38%) with MSP, 89 (30.8%) of whom were affected by psoriatic arthritis. Of the 289 patients, 267 (92.3%) were deemed eligible for a systemic treatment, and 228 (85.4%) of them started a systemic treatment as monotherapy. The therapies administered were as follows: cyclosporine to 65 (28.5%); methotrexate to 59 (25.8%); etanercept to 33 (44%); adalimumab to 25 (33.3%); ustekinumab to 17 (22.6%); acitretin to 29 (12.7%); golimumab to one (1.3%). CONCLUSIONS: Our data show a composite distribution of patients eligible for a systemic therapy and attending for the first time our center. The traditional drugs were more frequently administered (67.1%) as compared to biological ones (32.9%).

Original languageEnglish
Pages (from-to)596-602
Number of pages7
JournalGiornale Italiano di Dermatologia e Venereologia
Volume151
Issue number6
Publication statusPublished - Dec 1 2016

Fingerprint

Ambulatory Care Facilities
Psoriasis
Matrix Metalloproteinases
Therapeutics
Acitretin
Psoriatic Arthritis
Skin Diseases
Methotrexate
Cyclosporine
Databases
Pharmaceutical Preparations

Keywords

  • Biological products
  • Drug therapy
  • Psoriasis

ASJC Scopus subject areas

  • Medicine(all)
  • Dermatology

Cite this

@article{7cbbe603ece047ada61b6ee8b8350f46,
title = "Clinical characteristics and systemic therapies administered to first-time patients at a tertiary psoriasis outpatient clinic",
abstract = "BACKGROUND: The aim of this study was to describe the clinical characteristics and the systemic therapies given to a cohort of patients attending for the first time our tertiary psoriasis outpatient clinic. METHODS: Data were extracted from an electronic database where the patients, mostly eligible for systemic therapies, are consecutively recorded. Based on skin disease severity the subjects were classified into three groups: group 1, mild psoriasis (MP; Psoriasis Area Severity Index [PASI]≤5); group 2, mild-to-moderate psoriasis (MMP; 5<PASI<10); group 3, moderate-to-severe psoriasis (MSP; PASI>10). RESULTS: Of the 289 patients studied, 88 (30.4{\%}) presented with MP, 91 (31.5{\%}) with MMP, and 110 (38{\%}) with MSP, 89 (30.8{\%}) of whom were affected by psoriatic arthritis. Of the 289 patients, 267 (92.3{\%}) were deemed eligible for a systemic treatment, and 228 (85.4{\%}) of them started a systemic treatment as monotherapy. The therapies administered were as follows: cyclosporine to 65 (28.5{\%}); methotrexate to 59 (25.8{\%}); etanercept to 33 (44{\%}); adalimumab to 25 (33.3{\%}); ustekinumab to 17 (22.6{\%}); acitretin to 29 (12.7{\%}); golimumab to one (1.3{\%}). CONCLUSIONS: Our data show a composite distribution of patients eligible for a systemic therapy and attending for the first time our center. The traditional drugs were more frequently administered (67.1{\%}) as compared to biological ones (32.9{\%}).",
keywords = "Biological products, Drug therapy, Psoriasis",
author = "Claudio Bonifati and Dario Graceffa and Viviana Lora and Elisa Maiani",
year = "2016",
month = "12",
day = "1",
language = "English",
volume = "151",
pages = "596--602",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - Clinical characteristics and systemic therapies administered to first-time patients at a tertiary psoriasis outpatient clinic

AU - Bonifati, Claudio

AU - Graceffa, Dario

AU - Lora, Viviana

AU - Maiani, Elisa

PY - 2016/12/1

Y1 - 2016/12/1

N2 - BACKGROUND: The aim of this study was to describe the clinical characteristics and the systemic therapies given to a cohort of patients attending for the first time our tertiary psoriasis outpatient clinic. METHODS: Data were extracted from an electronic database where the patients, mostly eligible for systemic therapies, are consecutively recorded. Based on skin disease severity the subjects were classified into three groups: group 1, mild psoriasis (MP; Psoriasis Area Severity Index [PASI]≤5); group 2, mild-to-moderate psoriasis (MMP; 5<PASI<10); group 3, moderate-to-severe psoriasis (MSP; PASI>10). RESULTS: Of the 289 patients studied, 88 (30.4%) presented with MP, 91 (31.5%) with MMP, and 110 (38%) with MSP, 89 (30.8%) of whom were affected by psoriatic arthritis. Of the 289 patients, 267 (92.3%) were deemed eligible for a systemic treatment, and 228 (85.4%) of them started a systemic treatment as monotherapy. The therapies administered were as follows: cyclosporine to 65 (28.5%); methotrexate to 59 (25.8%); etanercept to 33 (44%); adalimumab to 25 (33.3%); ustekinumab to 17 (22.6%); acitretin to 29 (12.7%); golimumab to one (1.3%). CONCLUSIONS: Our data show a composite distribution of patients eligible for a systemic therapy and attending for the first time our center. The traditional drugs were more frequently administered (67.1%) as compared to biological ones (32.9%).

AB - BACKGROUND: The aim of this study was to describe the clinical characteristics and the systemic therapies given to a cohort of patients attending for the first time our tertiary psoriasis outpatient clinic. METHODS: Data were extracted from an electronic database where the patients, mostly eligible for systemic therapies, are consecutively recorded. Based on skin disease severity the subjects were classified into three groups: group 1, mild psoriasis (MP; Psoriasis Area Severity Index [PASI]≤5); group 2, mild-to-moderate psoriasis (MMP; 5<PASI<10); group 3, moderate-to-severe psoriasis (MSP; PASI>10). RESULTS: Of the 289 patients studied, 88 (30.4%) presented with MP, 91 (31.5%) with MMP, and 110 (38%) with MSP, 89 (30.8%) of whom were affected by psoriatic arthritis. Of the 289 patients, 267 (92.3%) were deemed eligible for a systemic treatment, and 228 (85.4%) of them started a systemic treatment as monotherapy. The therapies administered were as follows: cyclosporine to 65 (28.5%); methotrexate to 59 (25.8%); etanercept to 33 (44%); adalimumab to 25 (33.3%); ustekinumab to 17 (22.6%); acitretin to 29 (12.7%); golimumab to one (1.3%). CONCLUSIONS: Our data show a composite distribution of patients eligible for a systemic therapy and attending for the first time our center. The traditional drugs were more frequently administered (67.1%) as compared to biological ones (32.9%).

KW - Biological products

KW - Drug therapy

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=84994726235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994726235&partnerID=8YFLogxK

M3 - Article

VL - 151

SP - 596

EP - 602

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 6

ER -